Sana Biotechnology (SANA) announced that the U.S. Food and Drug Administration granted Fast Track designation for SC291 in relapsed/refractory systemic lupus erythematosus, which includes extrarenal ...

Under plans to extend the company’s cash runway into 2026, Sana said it has halted development of its CD19-directed allogeneic CAR T-cell therapy, dubbed SC291, in cancer and will instead focus ...

Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships ...

Sana Biotechnology (NASDAQ:SANA) reported encouraging early data from a Phase 1 study for its CD19-directed allogeneic CAR T therapy called SC291 in the treatment of chronic lymphocytic leukemia ...

Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships ...

Prioritize clinical and preclinical development on type 1 diabetes (UP421 and SC451), B-cell mediated autoimmune diseases (SC291), refractory B-cell malignancies (SC262), and the fusogen platform ...

[Click here for information about joining the class action] On November 4, 2024, Sana issued a press release announcing that it "will suspend development of both SC291 in oncology and of SC379 ...

The company is now concentrating its resources on advancing SC291, its anti-CD19 allogeneic CAR-T therapy, for the treatment of B-cell mediated autoimmune diseases (AID). This new focus has led to the ...

The Seattle-based firm will focus on its SC291 and UP421 programs for B-cell mediated autoimmune diseases and type 1 diabetes, respectively, with multiple data readouts expected in the next two years.